What is a potential risk associated with the use of iodinated contrast agents?

Iodinated contrast agents are commonly used in various imaging procedures, such as CT scans and angiography, to enhance the visibility of blood vessels and tissues. However, one of the significant risks associated with these agents is kidney damage, particularly in certain populations. This condition is known as contrast-induced nephropathy (CIN).

Patients who are particularly at risk for kidney damage from iodinated contrast include those with pre-existing kidney impairment, diabetes, dehydration, or those who are taking nephrotoxic medications. When iodinated contrast is administered, it can lead to an increase in serum creatinine levels and a decline in kidney function, sometimes resulting in acute kidney injury. Therefore, healthcare providers often assess kidney function prior to administering iodinated contrast and may take preventive measures, such as hydration or using alternative imaging modalities when feasible.

Understanding this risk is crucial in the field of radiology and for patient safety, as it impacts how radiologic procedures are planned and executed.